ES2280764T3 - Procedimiento de purificacion de interleucina-4 y sus muteinas. - Google Patents

Procedimiento de purificacion de interleucina-4 y sus muteinas. Download PDF

Info

Publication number
ES2280764T3
ES2280764T3 ES03738109T ES03738109T ES2280764T3 ES 2280764 T3 ES2280764 T3 ES 2280764T3 ES 03738109 T ES03738109 T ES 03738109T ES 03738109 T ES03738109 T ES 03738109T ES 2280764 T3 ES2280764 T3 ES 2280764T3
Authority
ES
Spain
Prior art keywords
buffer
interleukin
inclusion bodies
acid
refolding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03738109T
Other languages
English (en)
Spanish (es)
Inventor
Jorg Peters
Torsten Minuth
Hans-Georg Dellweg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Application granted granted Critical
Publication of ES2280764T3 publication Critical patent/ES2280764T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5406—IL-4

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES03738109T 2002-07-15 2003-07-02 Procedimiento de purificacion de interleucina-4 y sus muteinas. Expired - Lifetime ES2280764T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02015589A EP1382614A1 (en) 2002-07-15 2002-07-15 Process for the purification of interleukin-4 and its muteins
EP02015589 2002-07-15

Publications (1)

Publication Number Publication Date
ES2280764T3 true ES2280764T3 (es) 2007-09-16

Family

ID=29762614

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03738109T Expired - Lifetime ES2280764T3 (es) 2002-07-15 2003-07-02 Procedimiento de purificacion de interleucina-4 y sus muteinas.

Country Status (8)

Country Link
US (2) US20060134690A1 (enExample)
EP (2) EP1382614A1 (enExample)
JP (2) JP2006506332A (enExample)
AT (1) ATE352566T1 (enExample)
AU (1) AU2003244635A1 (enExample)
DE (1) DE60311470T2 (enExample)
ES (1) ES2280764T3 (enExample)
WO (1) WO2004007549A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1382614A1 (en) * 2002-07-15 2004-01-21 Bayer HealthCare AG Process for the purification of interleukin-4 and its muteins
US8189621B2 (en) 2006-05-12 2012-05-29 Microsoft Corporation Stack signaling to application with lack of requested bandwidth
US8144793B2 (en) 2006-12-12 2012-03-27 Microsoft Corporation Cognitive multi-user OFDMA
US8268604B2 (en) * 2007-12-20 2012-09-18 Abbott Point Of Care Inc. Compositions for forming immobilized biological layers for sensing
US8241697B2 (en) * 2007-12-20 2012-08-14 Abbott Point Of Care Inc. Formation of immobilized biological layers for sensing
KR101113495B1 (ko) 2008-01-23 2012-02-29 한미홀딩스 주식회사 인간 인터페론 베타의 정제방법
US20110034678A1 (en) * 2009-03-13 2011-02-10 Aerovance, Inc. Methods of renaturation of recombinant proteins
EP2427215A1 (en) * 2009-05-07 2012-03-14 Novo Nordisk Health Care AG Stable pharmaceutical compositions of peptide derivatized using an oxime linker
WO2012028525A2 (en) * 2010-08-30 2012-03-08 F. Hoffmann-La Roche Ag Method for producing a lipid particle, the lipid particle itself and its use
WO2012028524A2 (en) * 2010-08-30 2012-03-08 F. Hoffmann-La Roche Ag Method for producing a lipid particle, the lipid particle itself and its use
CN103320447A (zh) * 2013-05-20 2013-09-25 深圳市亚太兴实业有限公司 重组人白介素4基因、含重组人白介素4基因的工程菌发酵方法
CN108753753B (zh) * 2018-05-28 2022-04-22 中国林业科学研究院林业研究所 Lrr受体激酶-pxy的纯化方法
MX2022001975A (es) 2019-08-16 2022-03-11 Applied Molecular Transport Inc Composiciones, formulaciones y produccion y purificacion de interleucinas.
CN116874552B (zh) * 2023-09-08 2023-12-08 成都华任康生物科技有限公司 一种目标蛋白的纯化方法及其试剂盒和相关应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4137333A1 (de) * 1991-11-13 1993-05-19 W Prof Dr Sebald Therapeutische mittel, die antagonisten oder partielle agonisten des humanen interleukin 4 sind oder diese enthalten, hil-4-mutantenproteine sowie vefahren zu deren herstellung
NZ261571A (en) * 1993-02-04 1997-03-24 Denzyme Aps Producing correctly folded proteins using multiple denaturation and renaturation cycles
US5563057A (en) * 1994-10-31 1996-10-08 Wisconsin Alumni Research Foundation Method for refolding misfolded enzymes with detergent and cyclodextrin
JP3344618B2 (ja) * 1997-06-20 2002-11-11 株式会社エイチ・エス・ピー研究所 シャペロン発現プラスミド
US5932102A (en) * 1998-01-12 1999-08-03 Schering Corporation Immobilized metal, affinity chromatography
EP1382614A1 (en) * 2002-07-15 2004-01-21 Bayer HealthCare AG Process for the purification of interleukin-4 and its muteins

Also Published As

Publication number Publication date
DE60311470T2 (de) 2007-10-31
EP1382614A1 (en) 2004-01-21
AU2003244635A1 (en) 2004-02-02
US20110060128A1 (en) 2011-03-10
WO2004007549A1 (en) 2004-01-22
JP2006506332A (ja) 2006-02-23
ATE352566T1 (de) 2007-02-15
JP2011088922A (ja) 2011-05-06
DE60311470D1 (de) 2007-03-15
US20060134690A1 (en) 2006-06-22
EP1523500B1 (en) 2007-01-24
EP1523500A1 (en) 2005-04-20

Similar Documents

Publication Publication Date Title
ES2550363T3 (es) Derivados truncados de GLP-1 y su uso terapéutico
US20110060128A1 (en) Process for the purification of interleukin-4 and its muteins
ES2280857T3 (es) Replegado de polipeptidos.
ES2672770T3 (es) Derivados del péptido-1 similar al glucagón y su uso farmacéutico
JP6038248B2 (ja) プロリン／アラニンランダムコイルポリペプチドの生合成およびその使用
ES2281175T3 (es) Agonistas y antagonistas selectivos de il-2.
ES2651521T3 (es) Inhibidores proteicos de las rutas del complemento y de VEGF y métodos de uso de los mismos
ES2863278T3 (es) Proteínas terapéuticas biespecíficas para la reparación de tejidos
ES2468318T3 (es) FSH recombinante que incluye sialilaci�n en alfa 2,3- y alfa 2,6
CN112041330B (zh) 坎普他汀类似物及其医学用途
ES2611453T3 (es) Procedimiento para obtener G-CSF humano recombinante biológicamente activo
ES3049784T3 (en) Compstatin analogues and their medical uses
CN110494164B (zh) 一种靶向治疗TNF-α相关疾病的人抗体制剂
MX2011000847A (es) Proteinas conjugadas con eficacia prolongada in vivo.
CN101842109A (zh) 用a-b-c-d-衍生的肽和它们的治疗用途
PT94754B (pt) Processo de obtencao de inibidor de factor de necrose tumoral e de isolamento de genes que codificam o referido inibidor
ES2870802T3 (es) Métodos de replegado de proteínas a elevado pH
JP2023538807A (ja) 補体因子ｃ３の阻害剤及びそれらの医学的使用
JP2024532403A (ja) 腎障害または状態の治療のためのリラキシン類似体とバソプレシン類似体との組み合わせ
CN102272151B (zh) Crhr2肽激动剂及其用途
Alam et al. Expression and purification of a mutant human growth hormone that is resistant to proteolytic cleavage by thrombin, plasmin and human plasma in vitro
ES2208416T3 (es) Plegado de proteinas de membrana utilizando dos detergentes diferentes.
JP2005503139A (ja) 炎症性及び線維症性疾患治療用の精製組み換えヒトウテログロビンの製造方法
CN103446583A (zh) 一种治疗TNF-α相关疾病的人抗体制剂
JP2009242372A (ja) 均一な糖鎖構造を有するエリスロポエチン誘導体